What it measures: Total cholesterol minus HDL, which captures cholesterol carried by potentially atherogenic particles (including LDL and VLDL remnants).

Why we look at it: Non-HDL can track risk more reliably than LDL-C alone in some people, especially when triglycerides are elevated.

How we use it at Regenex: We use non-HDL alongside ApoB, LDL-P, triglycerides, blood pressure, and glucose markers to personalize nutrition, weight-management, and cardiometabolic strategies.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: The amount of cholesterol carried in HDL particles, often considered one piece of “protective” lipid transport.

Why we look at it: HDL helps provide context for lipid balance and ratios, but it’s not the only marker of protection or risk.

How we use it at Regenex: We interpret HDL with triglycerides, ApoB/non-HDL, insulin resistance markers, and lifestyle factors to identify the most actionable levers for improvement.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A measure of circulating triglycerides, which reflect how the body is transporting and storing energy.

Why we look at it: Higher triglycerides can be associated with insulin resistance and increased cardiometabolic risk, especially when HDL is low.

How we use it at Regenex: We trend triglycerides with TG/HDL ratio, fasting insulin, HbA1c, and liver markers to target nutrition, alcohol intake, sleep, and training adjustments.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: The amount of cholesterol carried in LDL particles (LDL-C), commonly labeled “bad cholesterol.”

Why we look at it: LDL-C can correlate with cardiovascular risk, but it may under- or over-estimate risk depending on particle number and other factors.

How we use it at Regenex: We use LDL-C as a starting point and rely on ApoB and/or LDL-P to refine risk and guide individualized changes and follow-up testing.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A ratio comparing total cholesterol to HDL cholesterol.

Why we look at it: Ratios can summarize lipid balance and can be useful for trending, though they don’t replace particle-based markers (ApoB/LDL-P).

How we use it at Regenex: We use this ratio as a quick trend marker and interpret it in the context of triglycerides, ApoB, and overall metabolic health.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A ratio comparing LDL cholesterol to HDL cholesterol.

Why we look at it: This ratio may offer added context on lipid balance, especially when compared over time.

How we use it at Regenex: We use it as a supporting trend alongside non-HDL and ApoB, and we prioritize interventions based on the full cardiometabolic picture.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A broad measure of total cholesterol in the blood (HDL + LDL + VLDL fractions).

Why we look at it: Total cholesterol alone can be misleading, but it can help frame the overall lipid story when paired with sub-fractions.

How we use it at Regenex: We use total cholesterol for context while focusing decisions on non-HDL, ApoB/LDL-P, triglycerides, and insulin resistance markers.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: ApoB estimates the number of atherogenic lipoprotein particles (each particle typically carries one ApoB).

Why we look at it: Particle number is strongly tied to risk because it reflects how many particles can enter and remain in arterial walls.

How we use it at Regenex: We use ApoB to refine risk when LDL-C looks “normal,” to guide follow-ups, and to track response to nutrition and therapy over time.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Lp(a) is a genetically influenced lipoprotein that can raise cardiovascular risk independent of standard cholesterol measures.

Why we look at it: Because it’s largely genetic, knowing your Lp(a) can change how aggressively we manage overall risk factors.

How we use it at Regenex: If Lp(a) is elevated, we emphasize broader risk reduction strategies and monitor other markers closely rather than relying on LDL-C alone.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: An estimate of the number of LDL particles (LDL-P) circulating in the blood.

Why we look at it: LDL particle number can identify “hidden risk” when LDL-C is low but particle count is high.

How we use it at Regenex: We use LDL-P (or ApoB) to clarify risk and tailor nutrition, weight management, and follow-up lab intervals.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: A calculated ratio combining neutrophils (an inflammatory immune cell) with HDL cholesterol.

Why we look at it: It may provide supporting context on inflammation-related cardiometabolic risk patterns.

How we use it at Regenex: We trend NHR with hs-CRP, CBC markers, TG/HDL, and lifestyle factors to understand inflammatory load and recovery.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated ratio derived from triglycerides and HDL that is often used as a proxy for insulin resistance.

Why we look at it: Higher values may suggest reduced metabolic flexibility and higher cardiometabolic risk.

How we use it at Regenex: We use TG/HDL with fasting insulin and HbA1c to decide whether nutrition, activity, sleep, and weight strategies should be prioritized first.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated index based on triglycerides and HDL (often expressed as log(TG/HDL)).

Why we look at it: It is sometimes used as a supporting indicator of lipid-related risk patterns.

How we use it at Regenex: We use AIP only as an add-on trend marker and place more weight on ApoB/LDL-P, non-HDL, and insulin resistance labs.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: Measures small, dense LDL particles, a subtype that can be more atherogenic in some contexts.

Why we look at it: A higher small-LDL burden can show up with insulin resistance and elevated triglycerides.

How we use it at Regenex: We use small LDL-P alongside TG/HDL and insulin markers to guide metabolic optimization priorities.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: An estimate of average HDL particle size.

Why we look at it: Size can provide context, but it’s not a direct measure of HDL function by itself.

How we use it at Regenex: We interpret HDL size with HDL particle number and metabolic markers rather than using it as a stand-alone decision point.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: Measures the concentration of larger HDL particles.

Why we look at it: In some people, higher large-HDL can correlate with more favorable metabolic patterns, but interpretation varies.

How we use it at Regenex: We use this as supporting context while focusing plans on insulin resistance, triglycerides, ApoB/LDL-P, and lifestyle factors.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: Measures larger VLDL particles, which are often associated with triglyceride-rich lipoprotein transport.

Why we look at it: Elevations can be seen in insulin resistance and fatty liver patterns.

How we use it at Regenex: We use large VLDL-P to support metabolic pattern recognition and to guide nutrition and weight-management adjustments.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: A calculated metric often expressed as (Total Cholesterol − HDL) ÷ HDL.

Why we look at it: It can summarize the balance between atherogenic cholesterol and HDL for trending.

How we use it at Regenex: We use it as a supporting trend marker while prioritizing ApoB/LDL-P and non-HDL for risk refinement.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: An estimate of average VLDL particle size.

Why we look at it: Larger VLDL size can correlate with triglyceride-rich particles and metabolic stress patterns.

How we use it at Regenex: We interpret VLDL size alongside triglycerides, liver enzymes, fasting insulin, and HbA1c to prioritize interventions.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: A relationship between LDL cholesterol and ApoB that helps estimate cholesterol-per-particle patterns.

Why we look at it: When LDL-C is “fine” but ApoB is high, it suggests many particles carrying less cholesterol each, which can increase risk.

How we use it at Regenex: We use LDL-C/ApoB to decide whether to focus on particle reduction strategies and to choose the best follow-up marker for monitoring.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated ratio combining uric acid with HDL cholesterol.

Why we look at it: It may add context to cardiometabolic risk because uric acid can correlate with metabolic stress in some individuals.

How we use it at Regenex: We trend this ratio with insulin, TG/HDL, and blood pressure to spot patterns that support targeted lifestyle changes.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated ratio comparing triglycerides to ApoB.

Why we look at it: It can provide hints about triglyceride burden relative to particle number, though interpretation depends on the full lipid and glucose picture.

How we use it at Regenex: We use it as a supporting signal when deciding which markers to emphasize during follow-up testing.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated relationship that estimates average cholesterol content per atherogenic particle.

Why we look at it: It can help distinguish between fewer cholesterol-rich particles vs many cholesterol-poor particles.

How we use it at Regenex: We use it to refine the lipid pattern story and to decide whether ApoB or non-HDL should be the primary trend metric for you.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A deeper breakdown of lipoprotein subfractions beyond standard LDL/HDL numbers.

Why we look at it: It can help clarify unusual lipid patterns and explain why standard numbers don’t match the clinical picture.

How we use it at Regenex: We use fractionation selectively when results are discordant or when we need a clearer particle pattern for decision-making.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: An endogenous compound associated with nitric oxide pathways that influence vascular function.

Why we look at it: Higher ADMA may be associated with endothelial dysfunction in certain contexts.

How we use it at Regenex: We interpret ADMA with blood pressure, kidney markers, inflammation labs, and lifestyle factors as part of a broader vascular health review.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: A marker associated with renal filtration and cardiometabolic context in some situations.

Why we look at it: It can provide additional kidney-related context beyond creatinine in select cases.

How we use it at Regenex: We interpret SDMA alongside creatinine, eGFR, urine markers (when available), hydration status, and blood pressure trends.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: An enzyme present in liver and bile ducts (and also in bone).

Why we look at it: Changes can be associated with bile flow patterns or bone turnover, so context matters.

How we use it at Regenex: We interpret ALP with GGT, bilirubin, ALT/AST, symptoms, and medications to clarify whether the signal is liver-related or non-liver.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A calculated comparison of albumin to globulin proteins.

Why we look at it: It can provide context on protein balance, liver production, and immune activity.

How we use it at Regenex: We use the A/G ratio with total protein, liver enzymes, and inflammatory markers to understand overall protein patterns and next steps.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A major blood protein made by the liver that supports fluid balance and transport.

Why we look at it: Low albumin may reflect liver production issues, kidney losses, inflammation, or nutrition status depending on context.

How we use it at Regenex: We interpret albumin with total protein, kidney markers, and inflammation markers to identify the most likely drivers.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A liver enzyme that can rise with liver inflammation or injury.

Why we look at it: Mild elevations are common and can relate to fatty liver, alcohol, medications, or intense exercise.

How we use it at Regenex: We trend ALT with AST, GGT, metabolic markers, and lifestyle factors to personalize liver-support strategies and follow-up timing.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Total bilirubin reflects bilirubin before and after the liver processes it.

Why we look at it: Elevations can relate to liver processing, bile flow, or red blood cell turnover.

How we use it at Regenex: We interpret total bilirubin alongside direct/indirect bilirubin, liver enzymes, and CBC markers to clarify the likely pattern.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A group of proteins that include immune-related antibodies and transport proteins.

Why we look at it: Higher or lower levels can be associated with immune activation, inflammation, or liver-related changes.

How we use it at Regenex: We use globulin with albumin, A/G ratio, and inflammation markers to decide whether more immune-focused labs are warranted.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: An enzyme found in liver and muscle tissue.

Why we look at it: AST can rise from liver stress or muscle breakdown, which is why context and pairing with ALT matters.

How we use it at Regenex: We interpret AST with ALT, training load, symptoms, and other liver labs to avoid over- or under-calling liver issues.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A liver enzyme that can reflect bile duct irritation and oxidative stress patterns.

Why we look at it: GGT can be sensitive to alcohol intake, medications, and metabolic stress.

How we use it at Regenex: We use GGT with ALT/AST, triglycerides, and insulin markers to identify lifestyle levers that most impact liver strain.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Indirect (unconjugated) bilirubin represents bilirubin prior to liver conjugation.

Why we look at it: It can help differentiate patterns related to liver processing vs red blood cell turnover.

How we use it at Regenex: We interpret indirect bilirubin with direct bilirubin, CBC markers, and clinical context to clarify next steps.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated ratio combining GGT with HDL cholesterol.

Why we look at it: It may add context on cardiometabolic stress patterns in some people.

How we use it at Regenex: We use this ratio as an optional trend marker and focus decisions on core liver enzymes, lipids, and insulin resistance labs.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated comparison between blood urea nitrogen (BUN) and creatinine.

Why we look at it: The ratio can help contextualize hydration status, protein intake, and kidney filtration patterns.

How we use it at Regenex: We interpret this ratio with eGFR, electrolytes, and clinical context to determine whether hydration or follow-up testing is needed.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: Blood calcium level, which supports bone health, muscle contraction, and nerve signaling.

Why we look at it: Abnormal calcium can relate to parathyroid signaling, vitamin D status, and kidney regulation.

How we use it at Regenex: We interpret calcium with albumin, vitamin D, magnesium, and kidney markers to understand whether the signal is true calcium imbalance or protein-related.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: CO₂ (bicarbonate) helps assess acid-base balance.

Why we look at it: It can shift with kidney regulation, breathing patterns, or metabolic changes.

How we use it at Regenex: We interpret CO₂ with electrolytes and kidney markers to assess whether the pattern suggests dehydration, compensation, or another cause.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A waste product filtered by the kidneys and used to estimate kidney function.

Why we look at it: Creatinine is influenced by muscle mass and hydration, so single readings can be misleading.

How we use it at Regenex: We use creatinine with eGFR, BUN, and trend history to guide whether additional kidney evaluation is needed.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: An electrolyte involved in fluid balance and acid-base regulation.

Why we look at it: Chloride changes can be seen with dehydration, GI losses, kidney regulation, or certain medications.

How we use it at Regenex: We interpret chloride with sodium, potassium, and CO₂ to understand electrolyte patterns and hydration status.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A primary electrolyte that regulates fluid balance and nerve signaling.

Why we look at it: Abnormal sodium can reflect hydration shifts, kidney regulation, hormonal signaling, or medication effects.

How we use it at Regenex: We interpret sodium with other electrolytes and clinical context and may recommend follow-up if values are significantly abnormal.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Blood potassium level, a key electrolyte for heart rhythm, muscle contraction, and nerve signaling.

Why we look at it: Potassium can shift with hydration, kidney regulation, certain medications/supplements, and diet. Abnormal values can be clinically significant.

How we use it at Regenex: We interpret potassium with sodium, chloride, CO2 (bicarbonate), creatinine/eGFR, and your medication list to determine whether the result is likely dietary/hydration-related or needs follow-up.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: An estimate of kidney filtration rate calculated from creatinine (and sometimes age/sex variables depending on the equation used).

Why we look at it: eGFR helps identify reduced kidney filtration earlier than creatinine alone in many cases.

How we use it at Regenex: We trend eGFR with creatinine, BUN, electrolytes, blood pressure, and hydration status to decide if monitoring or additional kidney evaluation is appropriate.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A waste product from protein metabolism that is filtered by the kidneys.

Why we look at it: BUN can reflect kidney filtration, hydration status, and protein intake patterns. It is most useful when interpreted with creatinine and eGFR.

How we use it at Regenex: We interpret BUN with creatinine/eGFR and the BUN/creatinine ratio to determine whether values suggest dehydration, diet/protein effects, or possible kidney stress.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A sensitive marker of systemic inflammation.

Why we look at it: Higher hs-CRP can be associated with increased cardiovascular risk and inflammatory burden.

How we use it at Regenex: We use hs-CRP with lipid markers, glucose/insulin, and lifestyle factors to prioritize recovery, sleep, nutrition, and stress strategies.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A general marker of inflammation based on how quickly red blood cells settle in a tube.

Why we look at it: ESR can rise with inflammatory or infectious processes and is less specific than hs-CRP.

How we use it at Regenex: We use ESR to add context when symptoms or other labs suggest inflammation and to trend broad inflammatory patterns.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A calculated index using neutrophils, lymphocytes, and platelets from a CBC.

Why we look at it: It summarizes immune-inflammatory balance and can provide context in chronic inflammation patterns.

How we use it at Regenex: We trend SII with hs-CRP and CBC differentials to monitor inflammatory load and recovery over time.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A ratio combining monocytes (immune cells) with HDL cholesterol.

Why we look at it: It may reflect inflammatory cardiometabolic patterns in certain populations.

How we use it at Regenex: We interpret MHR as a supporting trend and focus decisions on core cardiometabolic and inflammation markers.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated ratio of CRP to albumin.

Why we look at it: It can provide context on inflammation relative to protein/nutritional status.

How we use it at Regenex: We use CAR as an add-on trend marker when interpreting inflammatory burden and recovery patterns.

Method: Calculated from standard lab values. This ratio supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated ratio of platelets to lymphocytes from a CBC.

Why we look at it: Used as a general inflammation and physiologic stress trend marker in some approaches.

How we use it at Regenex: We interpret PLR alongside hs-CRP, CBC patterns, and symptoms to monitor change over time.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated index typically combining neutrophils, monocytes, and lymphocytes.

Why we look at it: Used as a supporting marker for systemic inflammation trends.

How we use it at Regenex: We use SIRI as a trend metric alongside hs-CRP and clinical context rather than a stand-alone diagnostic marker.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: Total testosterone in the blood (includes both bound and unbound fractions).

Why we look at it: Supports evaluation of androgen status related to energy, libido, mood, strength, and body composition.

How we use it at Regenex: We interpret total testosterone with SHBG, free/bioavailable testosterone, estradiol, DHEA-S, symptoms, and goals to guide hormone optimization decisions and monitoring.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: SHBG is a binding protein that controls how much testosterone and estradiol are free (active) versus bound.

Why we look at it: Changes in SHBG can make total testosterone look “normal” while free testosterone is low (or vice versa).

How we use it at Regenex: We use SHBG to calculate free/bioavailable testosterone and to identify drivers such as insulin resistance, thyroid patterns, liver function, and certain medications.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: The fraction of testosterone that is readily available to tissues (free + loosely albumin-bound).

Why we look at it: Bioavailable testosterone can track symptoms more closely than total testosterone for some people.

How we use it at Regenex: We use this marker to better match therapy decisions to symptoms and to monitor response over time alongside SHBG and estradiol.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A stable adrenal androgen that serves as a precursor for testosterone and estrogen pathways.

Why we look at it: Low or high DHEA-S can be associated with adrenal output patterns, stress physiology, and androgen symptoms.

How we use it at Regenex: We interpret DHEA-S with testosterone, symptoms, sleep/stress factors, and thyroid markers to guide supportive strategies and monitoring.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: The unbound fraction of testosterone that is considered biologically active.

Why we look at it: Free testosterone helps clarify androgen status when total testosterone is affected by SHBG changes.

How we use it at Regenex: We use free testosterone (measured or calculated) with SHBG and total testosterone to personalize hormone optimization, fitness, and weight-management planning.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A pituitary hormone involved in ovarian function and spermatogenesis.

Why we look at it: FSH provides context on gonadal signaling and can help evaluate fertility and certain hormone patterns.

How we use it at Regenex: We interpret FSH with LH, estradiol, progesterone (where relevant), testosterone, age, and symptoms to understand signaling vs production patterns.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: The free fraction of PSA in the blood.

Why we look at it: Free PSA can add context to total PSA results in certain scenarios and may help risk stratification when PSA is elevated.

How we use it at Regenex: We interpret free PSA with total PSA, trend history, age, symptoms, and clinical context and may recommend appropriate follow-up with a qualified provider if abnormal.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Progesterone level, a key hormone in menstrual cycle regulation and pregnancy support; also present in men at lower levels.

Why we look at it: Progesterone supports cycle assessment, luteal phase evaluation, and symptom patterns such as sleep and mood changes.

How we use it at Regenex: We interpret progesterone with cycle timing (if applicable), estradiol, LH/FSH, symptoms, and goals to personalize care planning.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Total PSA level in the blood.

Why we look at it: PSA is used as a screening/monitoring marker for prostate-related evaluation and requires contextual interpretation.

How we use it at Regenex: We interpret PSA trends with age and symptoms and coordinate follow-up recommendations with appropriate clinical guidelines and providers when needed.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A pituitary hormone that signals the ovaries/testes to produce sex hormones.

Why we look at it: LH helps clarify whether hormone patterns are related to signaling from the brain vs production at the gonads.

How we use it at Regenex: We interpret LH with FSH, testosterone/estradiol, and symptoms to understand primary vs secondary hormone pattern possibilities.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A pituitary hormone that can influence reproductive signaling and sexual function when elevated.

Why we look at it: High prolactin can be associated with libido changes, menstrual changes, infertility patterns, and sometimes medication effects.

How we use it at Regenex: We interpret prolactin with thyroid markers, sex hormones, medication list, and symptoms to decide whether repeat testing or follow-up is appropriate.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A calculated estimate of androgen activity using total testosterone and SHBG.

Why we look at it: FAI is commonly used when evaluating androgen symptoms in women and can support pattern recognition.

How we use it at Regenex: We use FAI alongside free/bioavailable testosterone, symptoms, and metabolic markers to guide next steps and monitoring.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated relationship between testosterone and estradiol.

Why we look at it: The balance between androgens and estrogens can influence symptoms like mood, libido, water retention, and body composition.

How we use it at Regenex: We use T:E2 as a supporting trend marker alongside absolute hormone levels and symptoms to guide personalized optimization strategies.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A steroid hormone involved in adrenal and gonadal hormone pathways.

Why we look at it: It can help evaluate certain adrenal/androgen pathway patterns when symptoms or other labs suggest it.

How we use it at Regenex: We interpret 17-OHP with DHEA-S, testosterone, symptoms, and clinical context to decide if further endocrine evaluation is needed.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A primary estrogen hormone that influences reproductive health, bone health, mood, and metabolic patterns.

Why we look at it: Estradiol is central to hormone balance in women and relevant in men when evaluating symptoms and optimizing therapy.

How we use it at Regenex: We interpret estradiol with testosterone, SHBG, progesterone (if applicable), symptoms, and goals to guide individualized care plans.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A hormone produced by ovarian follicles that helps estimate ovarian reserve.

Why we look at it: AMH can provide context for fertility planning and certain reproductive health evaluations.

How we use it at Regenex: We interpret AMH with age, cycle history, and other reproductive hormones and may recommend follow-up with the appropriate specialist depending on goals.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A more sensitive estradiol measurement designed to detect lower levels than standard assays.

Why we look at it: It can be useful when estradiol levels are expected to be low (often relevant in some male and postmenopausal contexts).

How we use it at Regenex: We use this test when standard estradiol may lack resolution and we need more precise trending for decision-making.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Blood mercury level to assess recent exposure.

Why we look at it: Elevated mercury can be relevant in certain symptom patterns and may influence neurologic and endocrine function.

How we use it at Regenex: We use this as a targeted exposure screen when history or symptoms suggest it, and interpret it with other labs and exposure sources (diet, occupation, environment).

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: A fasting insulin measurement used to assess insulin sensitivity and metabolic balance.

Why we look at it: Insulin often rises before glucose or HbA1c becomes abnormal, making it useful for earlier metabolic risk detection.

How we use it at Regenex: We interpret insulin with fasting glucose, HbA1c, TG/HDL, and body composition goals to personalize nutrition and weight strategies.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Antibodies that can indicate autoimmune activity affecting the thyroid (commonly TPO and/or Tg antibodies depending on the panel).

Why we look at it: Autoimmune thyroid patterns can explain symptoms even when standard thyroid hormone levels look “in range.”

How we use it at Regenex: We interpret thyroid antibodies with TSH, free T4/T3 (when available), symptoms, and family history to guide monitoring and next steps.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A point-in-time blood glucose measurement from plasma.

Why we look at it: Helps assess short-term glucose balance and supports insulin resistance evaluation when paired with fasting insulin and HbA1c.

How we use it at Regenex: We interpret plasma glucose with insulin and HbA1c and trend changes after nutrition, activity, and weight-management interventions.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Blood glucose concentration at a single time point (often fasting when ordered for metabolic evaluation).

Why we look at it: Elevated glucose can suggest impaired glucose regulation and is best interpreted alongside insulin and HbA1c.

How we use it at Regenex: We use glucose to establish baseline metabolic status and to track how nutrition, activity, sleep, and weight strategies are working.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: An estimate of average blood sugar over ~2–3 months based on hemoglobin glycation.

Why we look at it: Supports detection and monitoring of prediabetes/diabetes patterns and long-term glucose control trends.

How we use it at Regenex: We interpret HbA1c with fasting glucose, insulin, and clinical context and use it for trend-based goal setting.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A calculated conversion of HbA1c into an estimated average glucose value (mmol/L).

Why we look at it: Makes HbA1c easier to interpret and communicate as a day-to-day glucose estimate.

How we use it at Regenex: We use eAG as a patient-friendly trend metric alongside HbA1c and fasting labs.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated conversion of HbA1c into an estimated average glucose value (mg/dL).

Why we look at it: Helps translate HbA1c into a more intuitive glucose number for many people.

How we use it at Regenex: We use eAG as a quick trend marker while making decisions based on the full metabolic panel.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A waste product of purine metabolism measured in the blood.

Why we look at it: Higher uric acid can correlate with gout risk and may be associated with metabolic stress patterns in some individuals.

How we use it at Regenex: We interpret uric acid with insulin resistance markers, blood pressure, kidney labs, and dietary patterns to choose the most practical interventions.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Fasting insulin level.

Why we look at it: Insulin can elevate early in insulin resistance before glucose becomes abnormal.

How we use it at Regenex: We use fasting insulin with glucose, HbA1c, TG/HDL, and weight goals to personalize nutrition and activity plans.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A calculated calcium value adjusted for albumin level to estimate physiologically relevant calcium status.

Why we look at it: Helps clarify calcium interpretation when albumin is abnormal.

How we use it at Regenex: We use corrected calcium with vitamin D, magnesium, kidney markers, and symptom context to decide if further evaluation is needed.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated index derived from fasting triglycerides and glucose used as an estimate of insulin resistance.

Why we look at it: Higher TyG values can suggest reduced insulin sensitivity and increased cardiometabolic risk patterns.

How we use it at Regenex: We trend TyG alongside fasting insulin and HbA1c to validate progress from diet, exercise, and weight interventions.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A hormone produced by fat cells involved in appetite signaling and energy balance.

Why we look at it: High or low leptin can be associated with weight regulation challenges and metabolic dysfunction patterns.

How we use it at Regenex: We interpret leptin with body composition, insulin resistance markers, and hunger/satiety symptoms to personalize weight-management strategies.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: A specialty insulin-resistance estimate (panel-specific) used to refine insulin sensitivity assessment.

Why we look at it: Can provide additional context beyond single fasting glucose/insulin values.

How we use it at Regenex: We use this as supporting context when the clinical picture and standard labs are discordant and we need a clearer risk signal.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A hormone involved in insulin sensitivity, inflammation modulation, and fat metabolism.

Why we look at it: Lower adiponectin can be associated with higher metabolic risk in some individuals.

How we use it at Regenex: We interpret adiponectin with insulin, TG/HDL, and inflammatory markers to inform how aggressively we prioritize metabolic interventions.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: An estimate of average blood sugar over ~2–3 weeks based on glycation of serum proteins.

Why we look at it: Useful when HbA1c may be less reliable or when shorter-term changes need monitoring.

How we use it at Regenex: We use fructosamine to track rapid progress during metabolic changes or therapy adjustments alongside fasting glucose and insulin.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: The oxygen-carrying protein in red blood cells.

Why we look at it: Helps evaluate anemia patterns and oxygen delivery capacity; can shift with hydration status.

How we use it at Regenex: We interpret hemoglobin with hematocrit, RBC indices (MCV/MCH/MCHC/RDW), iron markers (when available), and symptoms like fatigue or shortness of breath.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Average amount of hemoglobin per red blood cell.

Why we look at it: Supports anemia pattern classification (often relevant to iron, B12, or folate-related patterns).

How we use it at Regenex: We interpret MCH with MCV, MCHC, RDW, and hemoglobin to determine whether further nutrient or iron studies may be useful.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Percent of blood volume made up of red blood cells.

Why we look at it: Helps assess anemia, hydration status, and certain blood disorders.

How we use it at Regenex: We interpret hematocrit with hemoglobin and RBC indices to understand whether low values likely reflect anemia patterns or other factors.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: The number of red blood cells in the blood.

Why we look at it: Supports anemia evaluation and oxygen delivery assessment.

How we use it at Regenex: We interpret RBC count with hemoglobin, hematocrit, and indices (MCV/MCH/MCHC/RDW) to identify likely deficiency patterns and next steps.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Average size of red blood cells.

Why we look at it: Helps classify anemia patterns (microcytic vs macrocytic), often related to iron vs B12/folate patterns.

How we use it at Regenex: We use MCV with RDW and other indices to decide whether nutrient testing or additional evaluation is warranted.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Average concentration of hemoglobin within red blood cells.

Why we look at it: Supports anemia pattern recognition alongside MCV/MCH/RDW.

How we use it at Regenex: We interpret MCHC with the full CBC and symptoms to guide whether iron or nutrient workup is appropriate.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Number of platelets in the blood, which support normal clotting and tissue repair.

Why we look at it: Platelets can shift with inflammation, iron status, and other physiologic stressors.

How we use it at Regenex: We interpret platelet count with inflammatory markers, RBC indices, and clinical context (symptoms, medications) to decide if follow-up is needed.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A measure of variation in red blood cell size.

Why we look at it: Higher RDW can suggest mixed nutrient deficiency patterns or evolving anemia in some contexts.

How we use it at Regenex: We interpret RDW with MCV and other indices to decide whether iron, B12, folate, or inflammatory evaluation may be helpful.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Average size of platelets.

Why we look at it: MPV can provide supporting context on platelet turnover and inflammatory patterns.

How we use it at Regenex: We interpret MPV with platelet count and CBC patterns as supportive information rather than a stand-alone marker.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: TSH, a pituitary hormone that signals the thyroid to produce T4 and T3.

Why we look at it: TSH is a primary screening marker for thyroid function patterns and can help flag underactive or overactive trends.

How we use it at Regenex: We interpret TSH with free T4 and free T3 (when available), symptoms, and thyroid antibodies to guide next steps and monitoring.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Free T3, the active thyroid hormone available to tissues.

Why we look at it: Free T3 can help explain symptoms when TSH is borderline or when conversion from T4 to T3 is a concern.

How we use it at Regenex: We use free T3 with free T4, TSH, and symptom patterns to personalize recommendations and track changes over time.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Total T4, including both bound and unbound thyroid hormone.

Why we look at it: Total T4 provides broader context on thyroid hormone availability and binding effects.

How we use it at Regenex: We interpret total T4 with T3 uptake or free hormone measures and clinical context, especially when binding proteins may be influencing results.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A calculated estimate that adjusts total T4 using T3 uptake to approximate free T4 activity.

Why we look at it: Helpful when total T4 is affected by binding proteins and you want a clearer picture of physiologic thyroid hormone effect.

How we use it at Regenex: We use the free T4 index as a supporting marker alongside TSH and free T3 to understand thyroid patterns.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: An indirect measure related to thyroid hormone binding that helps calculate the free T4 index.

Why we look at it: Provides context for how much thyroid hormone is bound to carrier proteins.

How we use it at Regenex: We use T3 uptake primarily to support calculation and interpretation of free hormone indexes when needed.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Antibodies against thyroid peroxidase, often associated with autoimmune thyroid activity.

Why we look at it: Can help identify autoimmune thyroid patterns that may contribute to symptoms even when TSH is in range.

How we use it at Regenex: We interpret TPO antibodies with TSH, T4/T3 markers, symptoms, and family history to guide monitoring frequency and care planning.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Antibodies targeting thyroglobulin, also associated with autoimmune thyroid activity.

Why we look at it: Supports a more complete autoimmune thyroid picture when combined with TPO antibodies.

How we use it at Regenex: We use Tg antibodies with other thyroid labs and symptoms to determine whether an autoimmune trend is present and how closely to monitor.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Ferritin, a marker of iron storage in the body.

Why we look at it: Low ferritin can contribute to fatigue, low exercise tolerance, and hair shedding; high ferritin can reflect inflammation or iron overload patterns.

How we use it at Regenex: We interpret ferritin with iron, TIBC, iron saturation, CBC indices, and inflammation markers to pinpoint likely drivers and next steps.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: The amount of circulating iron in the blood at the time of the draw.

Why we look at it: Helps evaluate iron status and supports anemia pattern workups when combined with other iron markers.

How we use it at Regenex: We interpret total iron with TIBC and saturation and repeat or expand testing if results do not match symptoms.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A measure of the blood’s capacity to bind and transport iron, often reflecting transferrin availability.

Why we look at it: Helps clarify iron deficiency patterns and improves interpretation of total iron.

How we use it at Regenex: We use TIBC with iron and saturation to understand whether iron status is low due to intake, absorption, or inflammation patterns.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: The percentage of transferrin binding sites occupied by iron, derived from iron and TIBC.

Why we look at it: A practical snapshot of iron availability to tissues.

How we use it at Regenex: We interpret saturation with ferritin and CBC to guide nutrition, supplementation decisions, and retesting intervals.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: Cortisol level, a key adrenal hormone involved in stress response, energy regulation, and metabolism.

Why we look at it: Abnormal cortisol patterns can relate to sleep issues, fatigue, and stress physiology, depending on timing of collection.

How we use it at Regenex: We interpret cortisol with symptoms, sleep schedule, and other metabolic markers to decide if lifestyle adjustments or additional testing is appropriate.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Body Mass Index, calculated from height and weight.

Why we look at it: BMI is a broad screening metric that does not capture body composition, but it can help with baseline risk stratification.

How we use it at Regenex: We use BMI as a starting point and pair it with waist measurements, labs, and goals to build a more personalized plan.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: Total white blood cell count.

Why we look at it: Helps assess immune activity, infection patterns, inflammation, and bone marrow output trends.

How we use it at Regenex: We interpret WBC with differential counts, symptoms, and recent illness history to decide if follow-up is needed.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Absolute neutrophil count.

Why we look at it: Neutrophils typically rise with acute infection, stress physiology, and inflammation patterns.

How we use it at Regenex: We interpret ANC with other differential markers and symptoms to understand whether the pattern is reactive or needs follow-up.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Neutrophil percentage in the white blood cell differential.

Why we look at it: Provides context for immune distribution and can shift with infection or physiologic stress.

How we use it at Regenex: We use percent values together with absolute counts for more accurate interpretation.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Absolute lymphocyte count.

Why we look at it: Lymphocytes are involved in viral defense and immune regulation and may shift with stress and illness patterns.

How we use it at Regenex: We interpret ALC with symptoms and other differential markers and trends over time.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Lymphocyte percentage in the white blood cell differential.

Why we look at it: Supports understanding of immune distribution shifts.

How we use it at Regenex: We interpret the percentage alongside the absolute value to avoid overinterpreting proportion changes.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Absolute monocyte count.

Why we look at it: Monocytes can rise with recovery from infection, chronic inflammation patterns, or certain stressors.

How we use it at Regenex: We interpret monocytes with CRP, other differentials, and clinical context to determine relevance.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Monocyte percentage in the white blood cell differential.

Why we look at it: Helps contextualize immune distribution changes.

How we use it at Regenex: We interpret percentage with absolute count and trends.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Absolute eosinophil count.

Why we look at it: Eosinophils can rise with allergies, asthma patterns, and certain parasitic exposures.

How we use it at Regenex: We interpret eosinophils with symptoms and history to decide if additional allergy or exposure evaluation is useful.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Eosinophil percentage in the white blood cell differential.

Why we look at it: Provides context for allergic or reactive immune patterns.

How we use it at Regenex: We interpret percentage with absolute counts and symptoms.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Absolute basophil count.

Why we look at it: Basophils can shift with allergic inflammation patterns and certain immune responses.

How we use it at Regenex: We interpret basophils as a supporting marker alongside eosinophils and clinical history.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Basophil percentage in the white blood cell differential.

Why we look at it: Adds context to immune distribution.

How we use it at Regenex: We interpret percentage with absolute basophil count and the full differential picture.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A calculated ratio of lymphocytes to monocytes.

Why we look at it: Can provide supporting context for immune balance and inflammatory trends.

How we use it at Regenex: We use LMR as a trend marker alongside CRP, CBC patterns, and symptoms rather than a stand-alone diagnostic marker.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated ratio between platelets and white blood cells.

Why we look at it: May provide supporting context in certain inflammatory or immune trend assessments.

How we use it at Regenex: We use this ratio as supplemental trend data alongside other inflammation and CBC markers.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated ratio of neutrophils to lymphocytes.

Why we look at it: Often used as a general inflammation and physiologic stress trend marker.

How we use it at Regenex: We interpret NLR with hs-CRP, symptoms, and recovery or illness patterns to track change over time.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated ratio of monocytes to lymphocytes.

Why we look at it: Can support pattern recognition related to immune balance and inflammation trends.

How we use it at Regenex: We use MLR as a supplemental trend metric interpreted with the full CBC differential and inflammation markers.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A calculated index combining neutrophils, lymphocytes, and platelets.

Why we look at it: Used as a supporting inflammation and stress response trend marker in some approaches.

How we use it at Regenex: We interpret NLPR with CRP and other CBC indices to monitor changes with lifestyle or treatment plans.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: An antibody marker that can be elevated in rheumatoid arthritis and other inflammatory conditions.

Why we look at it: Supports autoimmune screening when joint symptoms or inflammation patterns are present.

How we use it at Regenex: We interpret RF with symptoms and other autoimmune markers and recommend appropriate follow-up when clinically indicated.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Anti-CCP antibodies associated with rheumatoid arthritis risk and activity.

Why we look at it: More specific than rheumatoid factor in many contexts for RA evaluation.

How we use it at Regenex: We interpret anti-CCP with symptoms and other inflammatory markers and coordinate follow-up recommendations if positive.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A screening test for antibodies that may be associated with systemic autoimmune activity.

Why we look at it: Can support evaluation of autoimmune patterns when symptoms suggest it.

How we use it at Regenex: We interpret ANA in context, and if positive, may suggest additional specific antibody testing depending on symptoms.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A panel of antibodies used to screen for celiac disease patterns.

Why we look at it: Helps evaluate gluten-related autoimmune activity when digestive symptoms, anemia, or nutrient issues are present.

How we use it at Regenex: We interpret results with symptom history and may recommend confirmatory evaluation or dietary guidance as appropriate.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: IGF-1, a hormone influenced by growth hormone activity that relates to tissue repair, metabolism, and body composition.

Why we look at it: Can provide context for recovery capacity, lean mass patterns, and certain endocrine evaluations.

How we use it at Regenex: We interpret IGF-1 with age, training load, sleep, nutrition, and other hormone markers to guide a realistic plan and monitoring.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Homocysteine level, influenced by methylation pathways and B vitamin status.

Why we look at it: Elevated homocysteine can be associated with cardiovascular risk patterns and may suggest folate, B12, or B6 support needs.

How we use it at Regenex: We interpret homocysteine with B12, folate, and lifestyle factors to personalize nutrition and supplementation.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Folate level, a B vitamin needed for methylation and red blood cell formation.

Why we look at it: Low folate can contribute to anemia patterns and elevated homocysteine.

How we use it at Regenex: We interpret folate with CBC indices and homocysteine to guide dietary and supplementation strategies.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Folate stored in red blood cells, often reflecting longer-term folate status.

Why we look at it: Can be more stable than serum folate in some situations.

How we use it at Regenex: We use RBC folate when we want a broader view of folate sufficiency and interpret it with homocysteine and CBC patterns.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: Riboflavin status, a B vitamin involved in energy production and methylation support.

Why we look at it: Low B2 can affect energy metabolism and nutrient pathway efficiency.

How we use it at Regenex: We use B2 testing when diet patterns suggest risk and interpret it with other B vitamins and symptoms.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: Vitamin B6 level, important for neurotransmitter production, immune function, and homocysteine metabolism.

Why we look at it: Low B6 can contribute to fatigue and elevated homocysteine patterns.

How we use it at Regenex: We interpret B6 with homocysteine and other B vitamin markers to tailor nutrition and supplementation.

Method: Laboratory-developed test validated under CLIA and performed by qualified reference labs. Results support clinician interpretation and are not a stand-alone diagnosis.

What it measures: MMA, a functional marker that can rise when B12 is insufficient at the cellular level.

Why we look at it: Helps clarify B12 status when serum B12 is borderline or symptoms suggest deficiency.

How we use it at Regenex: We use MMA with B12 and CBC indices to guide next steps and confirm response to supplementation.

Method: Standard clinical laboratory measurement performed by CLIA-certified, CAP-accredited reference labs. Results support clinician interpretation, monitoring, and risk assessment and are not a stand-alone diagnosis.

What it measures: A composite scoring test intended to summarize health status across multiple biomarkers.

Why we look at it: Provides a snapshot metric that can help track progress over time.

How we use it at Regenex: We use scoring tools as motivation and trend support, while clinical decisions rely on the underlying labs and symptoms.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A composite assessment designed to estimate biologic aging trends.

Why we look at it: Helps contextualize lifestyle impacts on long-term health trajectory.

How we use it at Regenex: We use this as a trend metric to support goal setting for sleep, nutrition, movement, and stress management.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.

What it measures: A biologic age estimate based on selected biomarkers.

Why we look at it: May help frame progress and risk reduction priorities.

How we use it at Regenex: We use BioAge as a communication tool and focus clinical planning on the specific biomarkers driving the score.

Method: Calculated from standard lab values. This ratio or index supports clinician interpretation and trend monitoring and is not a stand-alone diagnosis.